Cost‐Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa‐2b Versus Peginterferon Alfa‐2b Monotherapy of HBeAg ‐Positive Chronic Hepatitis B in China

Chronic hepatitis B (CHB) refers to a global infectious disease caused by the hepatitis B virus. The treatment of CHB causes a heavy economic burden to society. To ensure the rational allocation of medical resources in the whole society and achieve the goal of patients' satisfaction and economy, this study aimed to evaluate the economics of de novo combination of tenofovir alafenamide fumarate (TAF) as the first-line nucleos(t)ide analogues (NAs) and peginterferon alfa-2b (PEG-IFNα-2b) versus PEG-IFNα-2b monotherapy of HBeAg-positive CHB in China. The Markov model was used to simulate the transition of HBeAg-positive CHB patients aged 30 in China under various health states using TreeAge Pro 2011 software. The cycle length was 1 year, and the cycle period of the model was 50 years. The model parameters included clinical efficacy, cost, transition probability and discount rate. Cost-effectiveness analysis was conducted through simulation of the total cost and quality adjusted life years (QALYs) of various treatment options through models. Simultaneously, one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were performed. De novo combination of TAF and PEG-IFNα-2b and PEG-IFNα-2b monotherapy resulted in 11.16 and 10.81 QALYs, with total costs of $55559.72 and $57670.23, respectively. De novo combination strategy for HBeAg-positive CHB patients can save costs and obtain more health outcomes. Sensitivity analyses showed the reliability of the results. From the perspective of the whole society, the de novo combination strategy of TAF and PEG-IFNα-2b for patients with HBeAg-positive CHB may be more cost-effective than PEG-IFNα-2b monotherapy.